Gene tests for better melanoma risk assessment
Part of Cancer, Skin clinical trials.
This trial studies whether certain gene patterns and a blood test can help predict how melanoma might behave. It is for people with a thicker melanoma (greater than 2 mm) that has not spread to lymph nodes or other parts of the body, and who are planning to have a sentinel lymph node biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have melanoma that was confirmed by a biopsy
- Your melanoma is thicker than 2 mm (a T3b or higher stage)
- Your melanoma has not spread to lymph nodes or other organs, shown by ultrasound, CT, or PET scan
- You have not had a sentinel lymph node biopsy yet
- You have not received any treatment before surgery (neoadjuvant therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
This study tests the genes of your cancer to learn more about advanced breast, lung, melanoma, or sarcoma tumors. It may help doctors find better ways to treat these cancers in the future.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial uses special lab tests to look for tumor “molecular fingerprints” in your tumor or blood sample. The goal is to help your care team choose more personalized treatment options based on those results.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.